Anavex Life Sciences
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -13,370 | -11,292 | -12,523 | -34,019 |
EBIT | -23,709 | -13,580 | -11,271 | |
Net Income | -13,243 | -11,196 | -12,111 | -11,620 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -12,464 | -5,856 | -12,120 | -6,658 |
Cash | 101,164 | 115,771 | 120,775 | 132,187 |
Basic Shares | 85,380 | 85,073 | 84,806 | 84,002 |
Annual Financials
| Values in thousands | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -45,293 | -47,498 | -50,942 | -37,375 |
EBIT | -95,879 | -47,498 | -47,619 | -74,830 |
Net Income | -43,002 | -47,491 | -47,978 | -37,909 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -2,949 | 122,858 | ||
Free Cash Flow | -30,812 | -27,785 | -24,237 | -30,383 |
Cash | 132,187 | 151,024 | 149,157 | 152,107 |
Basic Shares | 83,468 | 79,788 | 76,910 | 69,803 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.16 |
2025-03-31 | -$0.13 |
2024-12-31 | -$0.14 |
